Dr. Peter Kertes discusses the publication of the first year results of the CANTREAT study that investigates monthly vs treat-and-extend dosing of ranibizumab for wet AMD. 

 

Full reference:

Kertes, P. J., Galic, I. J., Greve, M., Williams, R. G., Rampakakis, E., Scarino, A., & Sheidow, T. (2019). Canadian Treat and Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-related Macular Disease: 1-Year Results of the Randomized CANTREAT Study. Ophthalmology. doi:10.1016/j.ophtha.2019.01.013